Lumida
/ACH
⌘K
ACH

ACH

ACH
$1.16USD+0.00%+0.00 today

MARKET CAP

89.2M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$12

AI Summary

Stalk
Buy NowMedium

ACH is in Stage 2 advancing with a repaired EMA regime and a clear HH/HL sequence, supported by a Bullish Pivot Point pattern signaling structural repair and mean‐reversion bias. Price just broke above a multi‐week consolidation with volume expansion and rising EMAs, offering a momentum continuation opportunity. Under a speculative execution style, participating in the breakout is warranted now, though overbought indications and potential false breakouts warrant vigilance.

  • Ended at-the-market equity issuance to prioritize cash collections.
  • Announced CEO succession and tax‐asset rights plan for stability.
  • Q2 revenue fell to $613.2 M from $681.9 M (-10%).
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Accendra Health (NYSE: ACH) is a healthcare services company focusing on patient care and related services. As a player in the healthcare sector, it aims to improve operational performance and financial stability in an increasingly challenging economic landscape. Accendra is currently navigating a transitional phase with a new CEO on the horizon, highlighting its focus on optimizing capital management and enhancing its operational strategies. Amidst the broader industry trend towards digital health integration and operational efficiencies, Accendra is attempting to solidify its market position.

Bull says

  • Ended at-the-market equity issuance to prioritize cash collections.
  • Announced CEO succession and tax‐asset rights plan for stability.
  • High institutional 13F ownership indicates strong investor confidence.
  • Dividend yield of ~1.1% appeals to income-seeking buyers.
  • Reduced debt by $385 M, improving leverage profile.
  • Management targets tighter capital allocation and cost cuts.

Bear says

  • Q2 revenue fell to $613.2 M from $681.9 M (-10%).
  • Adjusted EBITDA dropped to $60.1 M vs. $96.6 M prior year.
  • GAAP loss widened to $89.1 M; free cash flow -$25.1 M.
  • Leverage remains high, pressuring cash flow amid rate hikes.
  • Negative profitability and growth trends undermine margins.
  • Recent analyst downgrades reflect weak market sentiment.

Investment themes with ACH

Medical Devices +0.44%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH
Most Shorted Stocks +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 08-11-2026neutral

Transcript signals

Read full transcript analysis ›